Initial Experience with the Radiotracer 18F-Fluciclovine PET/CT in Ovarian Cancer

ObjectiveEarly and accurate staging of ovarian cancer is paramount to disease survival. Conventional imaging including FDG PET/CT are limited in the evaluation of small metastatic lesions. 18F-Fluciclovine has minimal urine and bowel excretion allowing optimal visualization of the abdomen and pelvis. This study examines 18F-fluciclovine uptake in known primary and recurrent ovarian cancer.MethodsSeven patients with a confirmed diagnosis of epithelial ovarian cancer underwent 18F-fluciclovine PET/CT imaging. Forty-one (41) lesions were identified with 18F-fluciclovine and confirmed to be true positive (n = 41). We aim to explore if 18F-fluciclovine uptake in ovarian lesions were greater than background uptake of bone marrow, blood pool, and bladder. Quantification analysis was performed to determine max and mean standard uptake values (SUVmax and SUVmean) of known and suspected lesions compared to SUVmean uptake of background structures.Results18F-Fluciclovine demonstrated 100% sensitivity (41/41) for uptake in known ovarian lesions. The average SUVmax (+/- SD) uptake of known ovarian lesions was 5.9 (+/- 2.6) and 5.1 (+/- 2.0) on early and delayed images, respectively. The average tumor SUVmax to SUVmean of background (+/- SD) (T:B) ratios on early and delay were 1.9 (+/- 0.8), 2.1 (+/- 0.9) for marrow; 3.8 (+/- 1.8), 3.4 (+/- 1.5) for aorta; and 8.4 (+/- 4.3), 1.5 (+/- 1.7) for bladder, respectively.Conclusion18F-Fluciclovine uptake in malignant ovarian lesions was above background levels suggesting its feasibility in the imaging of ovarian cancer. Due to increasing tracer washout via the urinary bladder over time, early imaging at 4 min post injection is favorable.